NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
⌛📢This weekend is your last chance to apply for our consumer vacancies in the Brain, Lung, Lymphoma and Skin Resear… https://t.co/vNzoGDQUQu
2 days ago -
Do you want to keep up-to-date with the latest NCRI news and updates? Sign up to receive our monthly #newsletter!… https://t.co/G8XJcqG9ic
2 days ago -
Looking for a reason to submit an abstract for #NCRI2019? We'll give you some: Now hurry up, the deadline is 1 Se… https://t.co/bXsV0OHatx
3 days ago
- 30 Jul 201960-second interview with NCRI CTRad's new Chair David Sebag-Montefiore
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 18 Jun 2019Register now for the NCRI Annual Lymphoma UK Trials Meeting: 1 November 2019
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 2 May 2019Registration open for NCRI Urological Cancers Trials Meeting 2019
- 2 May 2019Registration open for the NCRI Upper Gastrointestinal Cancer Trials Meeting 2019
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed